Combination Chemotherapy, Tacrolimus, and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant For Hematologic Cancer
This trial is active, not recruiting.
|Conditions||chronic myeloproliferative disorders, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes|
|Treatments||busulfan, cyclophosphamide, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, bone marrow ablation with stem cell support|
|Sponsor||Sidney Kimmel Comprehensive Cancer Center|
|Collaborator||National Cancer Institute (NCI)|
|Start date||May 2004|
|End date||January 2015|
|Trial size||92 participants|
|Trial identifier||NCT00134017, CDR0000440164, J0373, JHOC-03121504, JHOC-J0373, P01CA015396, P30CA006973|
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclophosphamide, mycophenolate mofetil, or tacrolimus after transplant may stop this from happening.
PURPOSE: This clinical trial is studying how well giving combination chemotherapy together with tacrolimus and mycophenolate mofetil works in treating patients who are undergoing a donor bone marrow transplant for hematologic cancer.
|Intervention model||single group assignment|
time frame: Day 100
Immune reconstitution and disease control
time frame: Survival
Male or female participants up to 65 years old.
DISEASE CHARACTERISTICS: - Diagnosis of 1 of the following hematologic malignancies: - Acute myeloid leukemia (AML), meeting 1 of the following criteria: - AML beyond first complete remission (CR1) - Refractory AML - AML arising from myelodysplastic syndromes (MDS) - Secondary AML - MDS - Refractory anemia with excess blasts with > 10% blasts in bone marrow - Acute lymphoblastic leukemia (ALL), meeting 1 of the following criteria: - ALL in CR1 with 1 of the following high-risk features: - Philadelphia chromosome (Ph)-positive disease - Less than 1 year of age at diagnosis - Cytogenetic abnormalities involving chromosome 11q23 - ALL beyond CR1 - Refractory ALL - Chronic myeloid leukemia beyond first chronic phase - Chronic myelomonocytic leukemia - Chronic lymphocytic leukemia - Stage III-IV disease - Does not meet criteria for other bone marrow transplantation (BMT) studies - Myeloproliferative disorders - Ph-negative disease - Hodgkin's or non-Hodgkin's lymphoma - Chemotherapy-resistant disease - Paroxysmal nocturnal hemoglobinuria with life-threatening thrombosis - Multiple myeloma - Stage II or III disease - Very high-risk disease - Having an unrelated donor is considered a high-risk condition - Meets medical criteria for myeloablative BMT for the Sidney Kimmel Comprehensive Cancer Center - Bone marrow donor available, meeting 1 of the following criteria: - Genotypically HLA-identical sibling - Phenotypically matched first-degree relative - Unrelated donor molecularly matched at HLA-A, -B, -C, -DRB1, and -DQB1 PATIENT CHARACTERISTICS: Age - 6 months to 65 years Performance status - Not specified Life expectancy - Not specified Hematopoietic - See Disease Characteristics Hepatic - Not specified Renal - Not specified Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - See Disease Characteristics Endocrine therapy - No concurrent dexamethasone as an antiemetic during immunosuppression therapy Radiotherapy - Not specified Surgery - Not specified Other - No concurrent immunosuppressants until ≥ 24 hours after the completion of cyclophosphamide (post-transplantation)
|Official title||HLA Matched Related and Unrelated Bone Marrow Transplantation With Busulfan/Cyclophosphamide and Post Transplantation Cyclophosphamide for Hematological Malignancies|
|Principal investigator||Leo Luznik, MD|
|Description||OBJECTIVES: Primary - Determine the optimal dose of post-transplant immunosuppression comprising high-dose cyclophosphamide, tacrolimus, and mycophenolate mofetil administered after myeloablative conditioning chemotherapy comprising busulfan and cyclophosphamide followed by allogeneic bone marrow transplantation in patients with high-risk hematologic malignancies. - Determine the incidence and severity of acute graft-versus-host disease in patients treated with this regimen. - Determine other toxic effects of this regimen in these patients. Secondary - Determine immune reconstitution in patients treated with this regimen. - Determine disease control in patients treated with this regimen. OUTLINE: This is a pilot study. Patients are stratified according to age (≤ 19 years old vs > 19 years old). - Myeloablative conditioning chemotherapy: Patients receive busulfan IV or orally 4 times daily on days -7 to -4 OR days -6 to -3 and cyclophosphamide IV over 1 hour once daily on days -3 to -1 OR days -2 and -1. - Allogeneic bone marrow transplantation: Patients undergo allogeneic bone marrow transplantation on day 0. - Immunosuppression therapy: Patients receive 1 of the following immunosuppressive treatment regimens: - Regimen 1: Patients receive high-dose cyclophosphamide IV over 1 hour on day 3. - Regimen 2: Patients receive high-dose cyclophosphamide IV over 1 hour on days 3 and 4. - Regimen 3: Patients receive high-dose cyclophosphamide as in regimen 2 and oral mycophenolate mofetil three times daily on days 5-35. - Regimen 4: Patients receive high-dose cyclophosphamide as in regimen 2 and mycophenolate mofetil as in regimen 3. Patients also receive tacrolimus IV or orally twice daily on days 5-50. After completion of study transplantation, patients are followed at 30 and 60 days, 6 months, 1 year, and then annually thereafter. PROJECTED ACCRUAL: Approximately 30-60 patients (approximately 5 per immunosuppressive treatment regimen) will be accrued for this study.|
Call for more information